2 results
Approved WMORecruiting
Primary objective:- To investigate if neo-adjuvant combination of talimogene laherparepvec and nivolumab will achieve a pathologic response rate of 45% complete responses (either *pathological complete response (pCR)* or *pathological near complete…
Approved WMORecruiting
To introduce 68Ga-PSMA-PET/CT scanning in risk stratification of prostate cancer patients assumed to be suitable for active surveillance.